… Up to our knowledge, this is the first real-world reported case of voxelotor use in sickle cell
disease patients with stage IV chronic kidney disease with the approved dose of voxelotor …

Full article: An expert review of voxelotor for the treatment of hemolytic anemia in patients
with sickle cell disease: ‘bridging the gap between laboratory data and patient related …

… in sickling and improved rheology, that voxelotor may have similar long-term benefits by …
of sickle cell disease, the mechanism of action of voxelotor, and the safety and efficacy data …

… To confirm the safety and efficacy of long-term voxelotor use, … they had access to voxelotor
through commercialization or a … placebo or voxelotor 900 mg, received voxelotor 1500 mg as …

… real-world effectiveness of voxelotor and describe the observed changes in laboratory and
clinical outcomes after ≥2 weeks of therapy. This study shows that voxelotor treatment was …

… Expected clinical efficacy is a key consideration in prescribing voxelotor for SCD. Clinical
trials demonstrated statistically significant benefits related to hemoglobin levels and markers of …

… Voxelotor is a first-in-class sickle hemoglobin polymerization inhibitor … voxelotor increases
hemoglobin and reduces markers of hemolysis. Emerging evidence suggests that voxelotor …

… cell sickling and leads to hemolysis, chronic anemia, and vaso-occlusive crises. Voxelotor,
a … To assess the safety and efficacy of long-term voxelotor use, we report an updated interim …

… voxelotor has a favorable benefit-risk profile for patients with SCD-related anemia and can
serve as a potential disease-… Studies comparing the long-term efficacy and safety of voxelotor …

… While the demonstrated efficacy of voxelotor and … strongly associated with the use of voxelotor
and crizanlizumab. This … are side effects of treatment with voxelotor. Although acute pain …